Select publications

Publications discussed by Dr Budd

Andersson M et al. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5- fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 1999;35(1):39-46. Abstract

Bhardwaj S et al. An intensive sequenced adjuvant chemotherapy regimen for breast cancer. Cancer Invest 1993;11(1):6-9. Abstract

Bull JM et al. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 1978;41(5):1649-57. Abstract

Buzdar A. The ATAC (‘arimidex’. tamoxifen, alone or in combination) trial in postmenopausal women with early breast cancer – updated efficacy results based on a median follow-up of 47 months. Breast Cancer Res Treat 2002; Abstract 13.

Chlebowski RT et al. Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy. Cancer Res 1979; 39(11):4503-6. Abstract

Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003;21(7):1-9. Abstract

Engelsman E et al. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). Eur J Cancer 1991;27:966-70. Abstract

Hutchins L et al. CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of Intergroup trial INT 0102. Proc ASCO 1998. Abstract

Roche PC et al. Concordance between local and central laboratory HER2 testing in the breast Intergroup trial N9831. J Natl Cancer Inst 2002;94(11):855-7. Abstract

Sledge GW et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An Intergroup trial (E1193). J Clin Oncol 2003;21(4):588-92. Abstract

Metronomic chemotherapy

Bocci G et al. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62(23):6938-43. Abstract

Ellis LM et al. Overview of angiogenesis: Biologic implications for antiangiogenic therapy. Semin Oncol 2001;28:94-104. Abstract

Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol 1992;3(2):89-96. Abstract

Fox SB et al. Angiogenesis: Pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol. 2001;2(5):278-89. Abstract

Gasparini G. Metronomic scheduling: The future of chemotherapy? Lancet Oncol 2001;2(12):733-40. Abstract

Gastl G et al. Angiogenesis as a target for tumor treatment. Oncology 1997;54(3):177-84. Abstract

Gately S, Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 2001;7(5):427-36. Abstract

Hahnfeldt P et al. Minimizing long-term tumor burden: The logic for netronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol 2003;220(4):545-554. Abstract

Hanahan D et al. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105(8):1045-7. Abstract

Jacobs SA et al. Response to low-dose paclitaxel after a novel, intensive induction regimen in patients with metastatic breast cancer. Proc ASCO 1998: Abstract

Kerbel RS et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001;20(1-2):79-86. Abstract

Kerschgens C. Low-low toxic chemotherapy in metastatic breast cancer (MBC). A phase II-trial with mini-dose adriamycin/cyclophosphamide (AC-MINI). Proc ASCO 1998:Abstract

Klement G et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002;8(1):221-32. Abstract

Koshizuka K et al. Effect of low dose weekly docetaxel in patients with recurrent breast cancer. Proc ASCO 2002:Abstract 1959.

Man S et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002;62(10):2731-5. Abstract

Mross K. Anti-angiogenesis therapy: Concepts and importance of dosing schedules in clinical trials. Drug Resist Updat 2000;3(4):223-235. Abstract

Rocca A et al. Low dose oral methotrexate (MTX) and cyclophosphamide (CTX) in metastatic breast cancer (MBC): An attempt to exploit the antiangiogenic activity of common chemotherapeutic agents. Proc ASCO 2001:Abstract 116.

Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist 2000;5 Suppl 1:20-7. Abstract

Rowinsky EK. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents. Drugs 2000;60 Suppl 1:1-14; discussion 41-2. Abstract

Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002;20(18):3906-27. Abstract

Home · Search